Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bender, JK, Cattoir, V, Hegstad, K, Sadowy, E, Coque, TM, Westh, H, Hammerum, AM, Schaffer, K, Burns, K, Murchan, S, Novais, C, Freitas, AR, Peixe, L, Del Grosso, M, Pantosti, A & Werner, G 2018, 'Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature' Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, vol. 40, pp. 25-39. https://doi.org/10.1016/j.drup.2018.10.002

APA

CBE

MLA

Vancouver

Author

Bender, Jennifer K ; Cattoir, Vincent ; Hegstad, Kristin ; Sadowy, Ewa ; Coque, Teresa M ; Westh, Henrik ; Hammerum, Anette M ; Schaffer, Kirsten ; Burns, Karen ; Murchan, Stephen ; Novais, Carla ; Freitas, Ana R ; Peixe, Luísa ; Del Grosso, Maria ; Pantosti, Annalisa ; Werner, Guido. / Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe : Towards a common nomenclature. In: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2018 ; Vol. 40. pp. 25-39.

Bibtex

@article{395af0d47d6f4f429efdf1617672c345,
title = "Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature",
abstract = "Vancomycin-resistant enterococci (VRE) are important nosocomial pathogens. Invasive VRE infections are difficult to treat since common therapeutic options including ampicillin and glycopeptides often fail. In vitro, most VRE remain susceptible to last-resort antibiotics such as linezolid, tigecycline and daptomycin. However, neither tigecycline nor linezolid act in a bactericidal manner, and daptomycin has proven activity only at high dosages licensed for treating enterococcal endocarditis. Despite these pharmacological and therapeutic limitations, reports on resistance to these last-resort drugs in VRE, and enterococci in general, have increased in recent years. In this review, we briefly recapitulate the current knowledge on the mode of action as well as the known and novel mechanisms of resistance and describe surveillance data on resistance to linezolid, tigecycline and daptomycin in enterococci. In addition, we also suggest a common nomenclature for designating enterococci and VRE with resistances to these important last-resort antibiotics.",
author = "Bender, {Jennifer K} and Vincent Cattoir and Kristin Hegstad and Ewa Sadowy and Coque, {Teresa M} and Henrik Westh and Hammerum, {Anette M} and Kirsten Schaffer and Karen Burns and Stephen Murchan and Carla Novais and Freitas, {Ana R} and Lu{\'i}sa Peixe and {Del Grosso}, Maria and Annalisa Pantosti and Guido Werner",
note = "Copyright {\circledC} 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.drup.2018.10.002",
language = "English",
volume = "40",
pages = "25--39",
journal = "Drug Resistance Updates",
issn = "1368-7646",
publisher = "Churchill Livingstone",

}

RIS

TY - JOUR

T1 - Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe

T2 - Towards a common nomenclature

AU - Bender, Jennifer K

AU - Cattoir, Vincent

AU - Hegstad, Kristin

AU - Sadowy, Ewa

AU - Coque, Teresa M

AU - Westh, Henrik

AU - Hammerum, Anette M

AU - Schaffer, Kirsten

AU - Burns, Karen

AU - Murchan, Stephen

AU - Novais, Carla

AU - Freitas, Ana R

AU - Peixe, Luísa

AU - Del Grosso, Maria

AU - Pantosti, Annalisa

AU - Werner, Guido

N1 - Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Vancomycin-resistant enterococci (VRE) are important nosocomial pathogens. Invasive VRE infections are difficult to treat since common therapeutic options including ampicillin and glycopeptides often fail. In vitro, most VRE remain susceptible to last-resort antibiotics such as linezolid, tigecycline and daptomycin. However, neither tigecycline nor linezolid act in a bactericidal manner, and daptomycin has proven activity only at high dosages licensed for treating enterococcal endocarditis. Despite these pharmacological and therapeutic limitations, reports on resistance to these last-resort drugs in VRE, and enterococci in general, have increased in recent years. In this review, we briefly recapitulate the current knowledge on the mode of action as well as the known and novel mechanisms of resistance and describe surveillance data on resistance to linezolid, tigecycline and daptomycin in enterococci. In addition, we also suggest a common nomenclature for designating enterococci and VRE with resistances to these important last-resort antibiotics.

AB - Vancomycin-resistant enterococci (VRE) are important nosocomial pathogens. Invasive VRE infections are difficult to treat since common therapeutic options including ampicillin and glycopeptides often fail. In vitro, most VRE remain susceptible to last-resort antibiotics such as linezolid, tigecycline and daptomycin. However, neither tigecycline nor linezolid act in a bactericidal manner, and daptomycin has proven activity only at high dosages licensed for treating enterococcal endocarditis. Despite these pharmacological and therapeutic limitations, reports on resistance to these last-resort drugs in VRE, and enterococci in general, have increased in recent years. In this review, we briefly recapitulate the current knowledge on the mode of action as well as the known and novel mechanisms of resistance and describe surveillance data on resistance to linezolid, tigecycline and daptomycin in enterococci. In addition, we also suggest a common nomenclature for designating enterococci and VRE with resistances to these important last-resort antibiotics.

U2 - 10.1016/j.drup.2018.10.002

DO - 10.1016/j.drup.2018.10.002

M3 - Journal article

VL - 40

SP - 25

EP - 39

JO - Drug Resistance Updates

JF - Drug Resistance Updates

SN - 1368-7646

ER -

ID: 55650826